Holen Sie sich die Stockscreener-App
4.99
0.80%
-0.04
Handel nachbörslich:
4.99
Schlusskurs vom Vortag:
$5.03
Offen:
$5.08
24-Stunden-Volumen:
108.59K
Relative Volume:
0.34
Marktkapitalisierung:
$93.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.67%
1M Leistung:
-24.85%
6M Leistung:
-14.41%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.78
$5.45
1-Wochen-Bereich:
$4.70
$5.45
52-Wochen-Spanne:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Firmenname
Kalaris Therapeutics Inc
Sektor
Branche
Telefon
650-249-2727
Adresse
628 MIDDLEFIELD ROAD, PALO ALTO
Vergleichen Sie KLRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.99 | 94.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-23 | Fortgesetzt | Piper Sandler | Neutral |
| 2025-05-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
Kalaris Therapeutics Inc Aktie (KLRS) Neueste Nachrichten
KLRS Sees New Analyst Rating: Citizens Initiates with Market Out - GuruFocus
Tools to assess Kalaris Therapeutics Inc.’s risk profileMarket Volume Report & Safe Swing Trade Setups - newser.com
Can trapped investors hope for a rebound in Kalaris Therapeutics Inc.Bull Run & Real-Time Chart Breakout Alerts - newser.com
Kalaris Therapeutics appoints Matthew Gall as chief financial officer By Investing.com - Investing.com UK
What MACD and RSI say about Kalaris Therapeutics Inc.Market Growth Review & Safe Swing Trade Setups - newser.com
How Kalaris Therapeutics Inc. stock performs in rate cut cycles2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Kalaris Therapeutics Appoints New CFO Matthew Gall - TipRanks
Kalaris Therapeutics appoints Matthew Gall as chief financial officer - Investing.com
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - The Manila Times
Kalaris (KLRS) names Matthew Gall CFO amid Phase 1b/2 nAMD study enrollment - Stock Titan
Analyzing Kalaris Therapeutics Inc. with risk reward ratio chartsJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
What’s next for Kalaris Therapeutics Inc. stock price2025 Short Interest & Target Return Focused Stock Picks - newser.com
Will Kalaris Therapeutics Inc. outperform the marketPortfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysWatch List & Real-Time Volume Trigger Notifications - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target - Investing.com
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Declines By 40.5% - MarketBeat
How resilient is Kalaris Therapeutics Inc. stock in market downturnsTrade Performance Summary & Safe Swing Trade Setups - newser.com
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Kalaris Therapeutics Inc. stock outlook for YEAR2025 Performance Recap & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-31 05:04:53 - newser.com
Identifying reversal signals in Kalaris Therapeutics Inc.Weekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Kalaris to Present at Stifel 2025 Annual Healthcare Conference - Investing News Network
Kalaris (Nasdaq: KLRS) to present at Stifel Healthcare Conference; CEO & CMO 3:20–3:50 ET - Stock Titan
Finanzdaten der Kalaris Therapeutics Inc-Aktie (KLRS)
Es liegen keine Finanzdaten für Kalaris Therapeutics Inc (KLRS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):